Liposomal amphotericin (AmBisome) 2 mg/kg three times weekly was compared with placebo as prophylaxis against fungal infection in patients undergoing chemotherapy or bone marrow transplantation (BMT) for haematological malignancies. Prophylaxis began on day 1 of chemotherapy and continued until neutrophils regenerated or infection was suspected. Of 161 evaluable patients, 74 received AmBisome and 87 received placebo. Proven fungal infections developed in no patients on AmBisome and in three on placebo (3.4%) (P ‫؍‬ NS). Suspected fungal infections requiring intervention with systemic antifungal therapy (usually amphotericin B) occurred in 31 patients on AmBisome (42%) and in 40 on placebo (46%) (P ‫؍‬ NS). Suspected deep-seated infections developed in 21 (28.3%) and 31 (35.6%) patients, respectively (P ‫؍‬ NS). Time to develop a suspected or proven deep-seated infection showed a trend in favour of AmBisome (P ‫؍‬ 0.11). Fifty patients had fungal colonisation (48 with Candida spp, two with Aspergillus spp) of at least one body site during prophylaxis; 15 patients while receiving AmBisome (20%) and 35 while on placebo (40%) (P Ͻ 0.01). Time to colonisation was significantly delayed in the group receiving AmBisome (P Ͻ 0.05). Treatment-related toxicity was modest and no additional toxicity was observed in patients receiving AmBisome. AmBisome 2 mg/kg three times weekly is safe and reduces fungal colonisation in patients receiving intensive chemotherapy or BMT. However, despite encouraging trends, prophylactic AmBisome did not lead to a significant reduction in fungal infection or in requirement for systemic antifungal therapy. Keywords: AmBisome; prophylaxis; neutropenia More than half the fatal infections in neutropenic patients are due to fungi 1 with candida and aspergillus the most commonly-observed pathogens. fungal infection increases with the severity and duration of neutropenia which, in the case of bone marrow transplantation (BMT) or chemotherapy for the treatment of haematological malignancies, can range from a few days to several weeks. The severe immunosuppression induced by high-dose corticosteroids given to recipients of allogeneic BMT to suppress graft-versus-host disease (GVHD) puts them at additional risk of fungal infections 2-4 whereas for patients receiving autologous stem cell support and treatment with growth factors the risk is much lower.
fungal infection increases with the severity and duration of neutropenia which, in the case of bone marrow transplantation (BMT) or chemotherapy for the treatment of haematological malignancies, can range from a few days to several weeks. The severe immunosuppression induced by high-dose corticosteroids given to recipients of allogeneic BMT to suppress graft-versus-host disease (GVHD) puts them at additional risk of fungal infections [2] [3] [4] whereas for patients receiving autologous stem cell support and treatment with growth factors the risk is much lower. 5 This provides a rationale for the prophylactic use of antifungal agents.
Orally administered agents such as the imidazoles, or non-absorbable amphotericin B, achieve only local decontamination and have little or no impact on invasive fungal infections. 6 A recent meta-analysis 7 has been conducted of 24 trials in which antifungals were used, either as prophylaxis or as empirical therapy, in patients with cancer complicated by neutropenia. This meta-analysis showed that amphotericin B decreased mortality significantly although the studies were small, as was the difference in the number of deaths. Antifungals as a group decreased the incidence of invasive fungal infections and fungal colonisation but had no significant impact on mortality.
In a recent, unblinded, prospective, multicentre study, the efficacy of aerosol amphotericin B as prophylaxis against invasive aspergillus infections in 382 neutropenic patients was unconvincing. 8 Fluconazole has been shown to reduce the incidence of deep-seated fungal infections in BMT patients, 9 ,10 but less so after chemotherapy. 11 Candida krusei and aspergillus infections are found as commonly in fluconazole-treated patients as in patients not receiving prophylaxis.
Amphotericin B has a broader antifungal spectrum than the imidazoles, but is limited by two key toxicities. First, the administration by infusion of conventional amphotericin B is associated with a variety of toxicities ranging from chills and fever to anaphylaxis. Although appropriate management can help to avoid or reduce these adverse effects, significant morbidity can occur and may require withdrawal of amphotericin. The second important safety issue for amphotericin B is nephrotoxicity. This is cumulative with progressive dosing, and limits the maximum daily dose and the duration of continued dosing.
AmBisome is a liposomal formulation in which the amphotericin B is bound into a phospholipid membrane.
AmBisome has an improved therapeutic index compared to conventional amphotericin B [12] [13] [14] [15] [16] [17] and has been shown to be of at least equal potency to conventional amphotericin B in clinical trials. 18, 19 In a randomised, double-blind, placebocontrolled, study in BMT patients, AmBisome at a dose of 1 mg/kg/day was associated with a trend towards a reduction in the incidence of proven fungal infection: 8% in the placebo group and 3% with AmBisome. The difference was not statistically significant, however, possibly because the patient sample was too small. 20 There was, however, a significant reduction in the AmBisome group in the proportion of patients with fungal colonisation, 33% vs 62% in the placebo group (P ϭ 0.05). 20 When AmBisome prophylaxis was studied in liver transplant patients, the difference in the overall incidence of fungal infections was significant, with none of the AmBisome-treated patients suffering an invasive fungal disease compared with 16% of the placebo group (P Ͻ 0.01). 21 These findings provided the rationale for the current placebo-controlled study of the efficacy and safety of AmBisome in the prevention of fungal disease in patients receiving myeloablative therapy with autologous or allogeneic progenitor cell transplantation for haematological malignancies.
Patients and methods

Patients
Five centres participated in the study: four in the UK and one in Ireland. The study was conducted in subjects receiving myeloablative therapy with autologous or allogeneic progenitor cell transplantation for haematological malignancies. All patients were considered to be at high risk for the development of fungal infection due to severe prolonged neutropenia or immunosuppression associated with the treatment of GVHD. Remission status at entry to the study, and details of prior chemotherapy, were not recorded.
Subjects were not eligible for inclusion in the study if they had evidence of fungal infection prior to enrollment or had received antifungal therapy within the previous 28 days. Broad-spectrum antibacterial therapy, antiviral therapy, and non-absorbable antifungal agents (eg nystatin suspension) were permitted during the study. The use of colony-stimulating factors was not restricted. Potassium supplementation was permitted if required. Patients undergoing allogeneic BMT received GVHD prophylaxis with either cyclosporin alone, cyclosporin plus methotrexate or, in some unrelated donor transplants, Campath 1H. The study was conducted according to Good Clinical Practice guidelines after full approval by the institutional ethical review committees of the participating centres. Written informed consent was obtained from all subjects.
Study protocol
Study design: The study was designed as a double-blind, placebo-controlled, randomised study, with patients receiving either AmBisome (Nexstar, UK) 2 mg per kg body weight, or matching placebo, three times weekly. This dosing regimen was selected on the basis of preliminary data suggesting that AmBisome was effective therapy for fungal infections at a dose of 1 mg/kg per day, and on the basis of ease of administration. Study prophylaxis began on the same day as, or within 24 h of, conditioning chemotherapy, and was continued until neutrophil recovery or failure of prophylaxis. The placebo used in this study was a mixture of glucose 50 mg/ml (Baxter), Vamin 9 Glucose, Vitalipid and Solvito (all from Pharmacia Upjohn) which resulted in an infusion solution indistinguishable in appearance from AmBisome. The randomisation schedule was held in sealed envelopes by each hospital pharmacist independent of treating physicians and patients.
Investigations: A medical history and physical examination were performed before the start of prophylaxis and the latter was repeated on completion of study therapy. Culture tests for fungal organisms were performed before the start of prophylaxis and, thereafter, once weekly and on completion of study therapy. Candida species and Aspergillus fumigatus/flavus were detected serologically. Antigen tests (Cand-Tec; Ramco, Houston, TX, USA) were performed to detect free candida glycoprotein antigen and mannan antigen in serum. Cultures were taken from urine, throat and stool. Haematologic assessments (haemoglobin, platelets, total and differential leucocyte counts) and blood chemistry (BUN, creatinine, total bilirubin, AST, ALT, alkaline phosphatase and electrolytes) were performed three times weekly. Patients were assessed for adverse events three times weekly and at the end of study therapy.
Additional investigations in patients withdrawn for suspected fungal infection:
The following additional investigations were undertaken as necessary: fungal blood cultures; CT scan or, if not feasible, an X-ray of chest and abdomen; bronchiolar lavage cultures in patients with findings suggestive of pulmonary involvement; biopsy, if possible, of any lesions suggestive of sites of fungal infection; microscopic evaluation and cultures of such biopsies.
Definitions: Fungal colonisation was defined as the isolation of a fungal pathogen by culture on routine microbiological investigation, not associated with clinical or other evidence of disease. Proven fungal infection was defined as the microbiological identification of a fungal pathogen associated with clinical or radiological evidence of a disease process likely to be caused by this pathogen. Suspected systemic fungal infection was defined as the presence of fever (Ͼ37.5°C) refractory to at least 96 h of therapy with broad-spectrum antibacterial agents or the presence of symptoms or signs consistent with invasive fungal infection, excluding superficial mucocutaneous infection, while on antibacterial therapy.
End points: Study prophylaxis was continued until one of the following had occurred: complete neutrophil regeneration (neutrophils Ͼ0.5 ϫ 10 9 /l for 3 consecutive days); a serious and non-resolving adverse event; a suspected or proven fungal infection; withdrawal either at the patient's request or at the investigator's discretion -in the latter event, there was a requirement for the investigator to record the rationale for the decision. In addition, for patients with GVHD, prophylaxis was continued until the daily steroid requirement was less than 100 mg prednisolone.
Efficacy assessment: Prophylactic efficacy was assessed by: (1) the number of confirmed fungal infections; (2) the number of suspected fungal infections defined as above; (3) the presence of fungal colonisation, defined as above, of any body site.
Safety assessment:
The safety analysis focused on (1) the incidence of adverse events that occurred in more than 10% of either arm; (2) adverse events judged likely to be due to the study drug. Renal toxicity was defined as an increase in serum creatinine to greater than twice baseline. Hypokalaemia was defined as a serum potassium level Ͻ2.5 mol/l at any time. Hypernatraemia and hyponatraemia were defined, respectively, as a serum sodium level of Ͼ150 mol/l and Ͻ130 mol/l. Hyperbilirubinaemia was defined as a total bilirubin level of Ͼ60 mol/l.
Statistical analysis:
The sample size was fixed as 80 patients in each arm. Primary end-point for calculating sample size was the number of suspected fungal infections. Assuming control group incidences of 20-50%, this would allow the detection of differences of 18-22% between the arms 22 at 80% power and ␣ ϭ 0.025. Stratification between various risk groups for development of fungal infection was not considered feasible with this sample size, nor was there any consensus at the time of writing the protocol as to the definition of these risk groups. The analysis was based on an intention-to-treat principle but included only those subjects eligible for inclusion who had received at least 1 day of prophylaxis. The incidences of efficacy and safety events were compared using 2 or Fisher's exact test. Means were presented with standard deviation and were compared with the Student's t-test or the Mann-Whitney test when a normal distribution could not be ensured. Times to development of efficacy or safety events were compared by Kaplan-Meier analysis, with differences tested using the log rank test. Analyses were performed using SAS6.10 or Statistica (Statsoft).
Results
In total, 170 patients were randomised and 163 were treated. Five patients randomised to receive AmBisome and two randomised to placebo were not treated. Reasons given were: cancellation of bone marrow transplant (2), delay in administering chemotherapy (2), other systemic antifungal prophylaxis (1), unknown (2). Two further patients had received systemic antifungal therapy within the previous 28 days and so were ineligible for evaluation. This left 161 evaluable patients, 74 who received AmBisome and 87 who received placebo.
All subjects began prophylaxis within 24 h of the start of chemotherapy. The characteristics of the groups were similar (Table 1) , and none of the observed differences was statistically significant, except that a greater proportion of subjects randomised to receive AmBisome had a serum creatinine Ͼ110 mol/l at the start of the study (11/74 compared with 3/87; P ϭ 0.01). Sixty-seven of 74 (90.5%) subjects randomised to receive AmBisome and 76/87 (87.4%) randomised to receive placebo became neutropenic (neutrophils Ͻ0.5 ϫ 10 9 /l) during study therapy. All other subjects were withdrawn from the study before neutropenia developed. Overall duration of neutropenia for all patients entered in to the study was not recorded as monitoring of blood counts ceased at the time of withdrawal or cessation of study medication, which was often before neutrophil recovery occurred. Forty-eight patients in the AmBisome arm and 54 patients in the placebo arm received corticosteroids at some point during the study. Thirteen patients in each arm received either G-CSF or GM-CSF.
Clinical success
In the placebo arm, 20 patients (23%) were maintained on prophylaxis until neutrophil recovery without evidence of fungal infection, compared with 27 (36%) in the AmBisome arm.
Proven fungal infection
In the placebo group, there were three proven fungal infections (3.4%): two systemic (candidaemia) and one superficial (oral candidiasis). There were no proven fungal infections in the AmBisome group (NS).
Suspected fungal infection
Systemic or superficial fungal infections were suspected in 40 (46%) and 31 (42%), respectively, of patients in the placebo and AmBisome groups. The number of suspected deep infections was 31 (35.6%) and 21 (28.3%), respectively, and of superficial infections nine (10.3%) and nine (12.2%). There was one further, unspecified, suspected infection in the AmBisome group. The Kaplan-Meier estimates of the proportion of patients in each group not developing a suspected or proven deep-seated infection showed a trend in favour of AmBisome (P ϭ 0.11) (Figure 1 ).
Fungal colonisation
Fungal colonisation of at least one site, occurring during the course of study prophylaxis, was twice as frequent among patients in the placebo, as in the AmBisome, group: 35 (40%) vs 15 (20%) (P Ͻ 0.01). Time to development of colonisation with a fungal pathogen was significantly delayed in the AmBisome group (P Ͻ 0.05) (Figure 2 ). Only patients with colonisation of a new body site were evaluated in this analysis. Candida spp comprised the vast majority of isolates; Aspergillus spp were isolated from two patients. In a large minority of the colonised patients, fungal isolates were obtained from two or three sites.
Other withdrawals
A further 32 patients were withdrawn from the study due, respectively, to patient's request (6,0); adverse event (immediate reaction) due to the study drug (1,5); venous occlusive disease (0,1), death (1,1); investigator's decision (reason unspecified; 8 AmBisome, 9 placebo).
Safety
Clinical toxicity: There were no statistically significant differences between the AmBisome and placebo arms in the incidences of the most frequently reported adverse events (Table 2 ). Other adverse events were relatively infrequent and again there were no significant differences between the two groups. Only infusion-related fever, hypokalaemia and nephrotoxicity were thought to be related to the study drug. Five patients in the AmBisome group and one in the placebo group experienced an immediate reaction to the first dose of study drug, were withdrawn from the study, and subsequently recovered. There were no significant differences between the AmBisome and placebo groups in any of the laboratory values measured, including nephrotoxicity, and only one patient developed hypokalaemia (Table  3) .
Mortality: There were 12 (14%) and 11 (15%) deaths, respectively, in the placebo and AmBisome groups. Only two of these deaths, one in each group, were considered due to failure of prophylaxis, ie to a possible or proven fungal infection probably acquired during the study. One of these deaths was due to pulmonary aspergillosis which was diagnosed 7 days after prophylactic AmBisome had been replaced with conventional amphotericin B. The other, in the placebo group, occurred on day 3 of the study. Another patient in the placebo group died on day 36, after withdrawal from the study. All the other deaths considered to be related to fungal infection occurred between 3 and 182 days after the end of the study. The 18 other deaths (nine in each group) were due to a variety of causes including: disease progression, GVHD, acute respiratory distress syndrome, venous occlusive disease, kidney and liver failure, gastro-intestinal haemorrhage. No death was considered related to the study drug.
Discussion
In this study, although the incidence of proven fungal infection was lower in the group receiving AmBisome prophylaxis than in the placebo group, the difference was not statistically significant. However, given the size of the population studied and the low incidence of confirmed fungal infection in the control group, this lack of significance is to be expected: the sample size was chosen to allow detection of differences of between 18% and 22% for control incidences of between 20% and 50%, respectively. An earlier study of AmBisome prophylaxis in patients undergoing BMT also documented a reduced incidence of proven fungal infections, 3% vs 8% in the placebo group, and also had a small sample size, and again this difference did not reach statistical significance. 20 The low incidence of proven fungal infection in the control group is at first sight somewhat surprising. Certainly some other studies in neutropenic patients have reported much higher incidences. 23, 24 It has been noted, however, that certain subpopulations are much more at risk than others. Marrow allograft recipients run the highest risk of invasive fungal infections, not only during neutropenia but also following transplantation, especially when receiving high-dose corticosteroids to suppress GVHD. [2] [3] [4] In contrast, patients receiving intensive chemotherapy followed by stem cell transplantation and cellular growth factor support are at lower risk. In a study of 219 of the latter patients, the median duration of neutropenia was 12 days and only 2.3% developed invasive fungal infections. 5 The present study included patients undergoing allogeneic BMT, autologous BMT, and stem cell transfusions with growth factor support. A recent study of antifungal prophylaxis with itraconazole vs fluconazole also documented a low rate of proven fungal infections in the control (fluconazole) group. 25 One explanation for these observations is that in Europe, in contrast to USA, most fungal infections in neutropenic patients are due to aspergillus rather than to candida. In general, aspergillus infection is difficult to confirm and generally requires tissue biopsy, a procedure which may be hazardous in neutropenic and thrombocytopenic patients.
The number of suspected deep-seated fungal infections was not significantly reduced by prophylactic AmBisome, despite the favourable trend. There was, however, a significant difference in the rate of fungal colonisation, 15 (20%) vs 35 (40%), respectively (P Ͻ 0.01), and time to development of a fungal pathogen (Candida spp in all but two cases) was significantly delayed in the AmBisome group. This is a potentially important observation since it has been shown that colonisation with Candida spp, particularly of multiple sites, is highly predictive of subsequent invasive candidiasis. [26] [27] [28] [29] [30] A similar significant reduction in colonisation was also noted in an earlier study with AmBisome in BMT recipients. 20 Interestingly, in neither study was a statistically significant reduction in infection rates seen as a result of reducing colonisation.
There were no significant differences between AmBisome and placebo in terms of clinical and laboratory toxicity. The only point of note was that five patients receiving AmBisome developed acute infusion-related reactions. This acute reaction rate is similar to that described by Prentice et al 18 using 3 mg/kg daily and compares extremely well with conventional amphotericin B. Thus the safety profile of AmBisome seems remarkably similar to that of placebo and is in marked contrast to previous experience with conventional amphotericin B which has limited use of the latter in a prophylactic setting.
We cannot rule out the possibility that a higher dose of AmBisome administered more frequently would be more effective at preventing deep-seated fungal infections in neutropenic subjects. It is also possible that a larger study would demonstrate a significant advantage for AmBisome, at any dose or frequency, over placebo. A study of the power required to detect the superiority of AmBisome with confidence using a similar dosing regimen would be extemely large. In addition, if AmBisome were to provide effective prophylaxis at doses higher than those used here any increase in the dose or frequency of administration would incur substantial additional costs for what may be modest clinical benefit. Nevertheless, further studies with AmBisome may be justified if current studies assessing cheaper alternative prophylactic antifungal strategies fail to demonstrate clinical efficacy.
We conclude that AmBisome administered at 2 mg/kg body weight three times weekly has a safety profile comparable to placebo and significantly reduces the incidence of fungal colonisation. However, despite encouraging trends, no significant reduction in the incidence of suspected or proven fungal infection was observed.
